These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 35941927)

  • 41. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
    Akaji K; Konno H
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anisodamine potently inhibits SARS-CoV-2 infection in vitro and targets its main protease.
    Wei W; Kong N; Liu MZ; Han T; Xu JF; Liu C
    Biochem Biophys Res Commun; 2022 Aug; 616():8-13. PubMed ID: 35636257
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Depicting the inhibitory potential of polyphenols from
    Ghosh R; Chakraborty A; Biswas A; Chowdhuri S
    J Biomol Struct Dyn; 2022 Jun; 40(9):4110-4121. PubMed ID: 33292085
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mapping major SARS-CoV-2 drug targets and assessment of druggability using computational fragment screening: Identification of an allosteric small-molecule binding site on the Nsp13 helicase.
    Freidel MR; Armen RS
    PLoS One; 2021; 16(2):e0246181. PubMed ID: 33596235
    [TBL] [Abstract][Full Text] [Related]  

  • 45. SARS-CoV-2 M
    Lis K; Plewka J; Menezes F; Bielecka E; Chykunova Y; Pustelny K; Niebling S; Garcia AS; Garcia-Alai M; Popowicz GM; Czarna A; Kantyka T; Pyrc K
    Int J Biol Macromol; 2024 May; 267(Pt 1):131392. PubMed ID: 38582483
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Promising SARS-CoV-2 main protease inhibitor ligand-binding modes evaluated using LB-PaCS-MD/FMO.
    Hengphasatporn K; Harada R; Wilasluck P; Deetanya P; Sukandar ER; Chavasiri W; Suroengrit A; Boonyasuppayakorn S; Rungrotmongkol T; Wangkanont K; Shigeta Y
    Sci Rep; 2022 Oct; 12(1):17984. PubMed ID: 36289271
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA.
    Bello M; Martínez-Muñoz A; Balbuena-Rebolledo I
    J Mol Model; 2020 Nov; 26(12):340. PubMed ID: 33184722
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.
    Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K
    Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tafenoquine and its derivatives as inhibitors for the severe acute respiratory syndrome coronavirus 2.
    Chen Y; Yang WH; Chen HF; Huang LM; Gao JY; Lin CW; Wang YC; Yang CS; Liu YL; Hou MH; Tsai CL; Chou YZ; Huang BY; Hung CF; Hung YL; Wang WJ; Su WC; Kumar V; Wu YC; Chao SW; Chang CS; Chen JS; Chiang YP; Cho DY; Jeng LB; Tsai CH; Hung MC
    J Biol Chem; 2022 Mar; 298(3):101658. PubMed ID: 35101449
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of Main Protease of Coronavirus SARS-CoV-2 (M
    Elekofehinti OO; Iwaloye O; Famusiwa CD; Akinseye O; Rocha JBT
    Curr Drug Discov Technol; 2021; 18(5):e17092020186048. PubMed ID: 32957889
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Natural Products-Based Drug Design against SARS-CoV-2 Mpro 3CLpro.
    Silva RC; Freitas HF; Campos JM; Kimani NM; Silva CHTP; Borges RS; Pita SSR; Santos CBR
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769170
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors.
    Ibrahim MAA; Abdelrahman AHM; Allemailem KS; Almatroudi A; Moustafa MF; Hegazy MF
    Protein J; 2021 Jun; 40(3):296-309. PubMed ID: 33387249
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Site mapping and small molecule blind docking reveal a possible target site on the SARS-CoV-2 main protease dimer interface.
    Liang J; Karagiannis C; Pitsillou E; Darmawan KK; Ng K; Hung A; Karagiannis TC
    Comput Biol Chem; 2020 Dec; 89():107372. PubMed ID: 32911432
    [TBL] [Abstract][Full Text] [Related]  

  • 54.
    Umadevi P; Manivannan S; Fayad AM; Shelvy S
    J Biomol Struct Dyn; 2022 Jul; 40(11):5053-5059. PubMed ID: 33372574
    [No Abstract]   [Full Text] [Related]  

  • 55. A computational study on active constituents of
    Shamsi S; Anjum H; Shahbaaz M; Khan MS; Ataya FS; Alamri A; Alhumaydhi FA; Husain FM; Rehman MT; Mohammad T; Islam A; Anjum F; Shamsi A
    J Biomol Struct Dyn; 2022 Oct; 40(17):7702-7713. PubMed ID: 33759703
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structure-Based Discovery and Structural Basis of a Novel Broad-Spectrum Natural Product against the Main Protease of Coronavirus.
    Zhang Y; Gao H; Hu X; Wang Q; Zhong F; Zhou X; Lin C; Yang Y; Wei J; Du W; Huang H; Zhou H; He W; Zhang H; Zhang Y; McCormick PJ; Fu J; Wang D; Fu Y; Lu X; Zhang T; Duan J; Qin B; Jiang H; Luo J; Zhang Y; Chen Q; Luo Q; Cheng L; Zhang Z; Zhang J; Li J
    J Virol; 2022 Jan; 96(1):e0125321. PubMed ID: 34586857
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Study of Drug Repurposing to Identify SARS-CoV-2 Main Protease (3CLpro) Inhibitors.
    Jo S; Signorile L; Kim S; Kim MS; Huertas O; Insa R; Reig N; Shin DH
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742913
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clean Grinding Technique: A Facile Synthesis and In Silico Antiviral Activity of Hydrazones, Pyrazoles, and Pyrazines Bearing Thiazole Moiety against SARS-CoV-2 Main Protease (M
    Abu-Melha S; Edrees MM; Riyadh SM; Abdelaziz MR; Elfiky AA; Gomha SM
    Molecules; 2020 Oct; 25(19):. PubMed ID: 33036293
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Structure-based drug design of an inhibitor of the SARS-CoV-2 (COVID-19) main protease using free software: A tutorial for students and scientists.
    Zhang S; Krumberger M; Morris MA; Parrocha CMT; Kreutzer AG; Nowick JS
    Eur J Med Chem; 2021 Jun; 218():113390. PubMed ID: 33812315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.